Microsoft Corp. is expanding its collaboration with NVIDIA to bring the power of generative AI, the cloud and accelerated computing to healthcare and life sciences organizations. The collaboration will bring together the global scale, security and advanced computing capabilities of Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite of computing platforms, software and services to help healthcare and life sciences organizations accelerate innovation and improve patient care. Harnessing the immense power of the cloud, cutting-edge AI and advanced computing capabilities, the collaboration aims to accelerate clinical research and drug discovery, enhance medical image-based diagnostic technology, and increase access to precision medicine.
“Microsoft is building on its longstanding collaboration with NVIDIA to empower the healthcare and life sciences industry with the power of Azure and generative AI, helping unlock new horizons for clinical research, drug discovery and patient care worldwide,” said Peter Durlach, corporate vice president, Health & Life Sciences, Microsoft. “Through this collaboration, we aim to help the industry unlock breakthroughs in healthcare, making care more precise, accessible and effective to deliver a meaningful difference in the lives of patients globally.”
“The convergence of AI, cloud computing and healthcare is set to transform patient care,” said Kimberly Powell, vice president of healthcare, NVIDIA. “Our collaboration with Microsoft will help unlock new possibilities and drive meaningful impact for patients worldwide.”
The expanded collaboration will extend opportunities for healthcare providers, pharmaceutical and biotechnology companies, and medical device developers to innovate rapidly across clinical research, drug discovery and care delivery with improved efficiency and effectiveness.
Faster drug discovery with NVIDIA BioNeMo on NVIDIA DGX Cloud, hosted on Microsoft Azure
Hosted on NVIDIA DGX Cloud on Azure, NVIDIA BioNeMo offers the quickest path to AI model development and deployment, accelerating the journey to AI-powered drug discovery. BioNeMo is a generative AI platform for drug discovery that simplifies and accelerates the training of models on proprietary data and scales the deployment of models for drug discovery applications. By analyzing vast datasets with unprecedented speed and precision, it can help scientists identify potential drug candidates more efficiently. The implications are profound: faster access to lifesaving therapies for patients worldwide.
SOURCE: PRNewswire